The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment Strategies in type 2 diabetes mellitus with stable ischemic heart disease: Impact of treatment strategy on cardiac mortality and myocardial infarction

Circulation

Volumn 120, Issue 25, 2009, Pages 2529-2540

  Chaitman, Bernard R ^a   Hardison, Regina M ^b   Adler, Dale ^c   Gebhart, Suzanne ^d   Grogan, Mary ^e   Ocampo, Salvador ^f   Sopko, George ^g   Ramires, Jose A ^h   Schneider, David ⁱ   Frye, Robert L ^j  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d EMORY UNIVERSITY   (United States)

^e BROWN UNIVERSITY   (United States)

^f INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ UNIVERSITY OF VERMONT   (United States)

^j MAYO CLINIC   (United States)

more..

Author keywords

Angioplasty; Bypass; Diabetes mellitus; Myocardial infarction; Prognosis

Indexed keywords

INSULIN;

ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DATA ANALYSIS; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; INSULIN TREATMENT; INTENSIVE CARE; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; STATISTICAL SIGNIFICANCE; BIOASSAY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; HEART MUSCLE ISCHEMIA; LONGITUDINAL STUDY; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; DEATH; DIABETES MELLITUS, TYPE 2; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN; KAPLAN-MEIERS ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 73949143669     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.913111     Document Type: Article

References (41)

1. Leal J, Gray AM, Clarke PM. Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J. 2009;30:834-839.
2. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR, on behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci. 2001;101:671-679.
3. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Association of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167: 1145-1151.
4. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: Aubert RE, Ballard DJ, Barrett-Connor E, et al, eds. Diabetes in America. 2nd ed. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 1995:233-257. NIH publication 95-1468.
5. Barsness GW, Gersh BJ, Brooks MM, Frye RL. Rationale for the revas-cularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol. 2006;97(suppl 12A): 31G-40G.
6. Magee MF, Isley WL. Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol. 2006;97(suppl 12A): 20G-30G.
7. Frye RL, August P, Brooks M, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TLZ, Molitch ME, Nesto RW, Sako EY, Sobel BE; BARI IID Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515.
8. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris C, Chaitman BR, Shaw L, Gosselin G, Nawaz Sh, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GBJ, Weintraub WS, for the COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356: 1503-1516.
9. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GBJ, Berman DS, Weintraub WS, on behalf of the COURAGE Trial Coinvestigators and Study Coordinators. Design and rationale of the Clinical Outcomes Utilizing Revascular-ization and Aggressive DruG Evaluation (COURAGE) trial: Veterans Affairs Cooperative Studies Program No. 424. Am Heart J. 2006;151: 1173-1179.
10. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ, for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol. 2006;97(suppl 12A):9G-19G.
11. Kim LS, King SB, Kent K. Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with mul-tivessel coronary artery disease in the BARI 2D trial. J Am Coll Cardiol Intv. 2009;2:384-392.
12. Schwartz L, Kip KE, Alderman E, Lu J, Bates ER, Srinivas V, Bach RG, Mighton LD, Feit F, King S, Frye RL, and the BARI 2D Study Group. Baseline coronary angiographic findings in the Bypass Angioplasty Re-vascularization Investigation 2 Diabetes Trial (BARI 2D). Am J Cardiol. 2009;103:632-638.
13. Brooks MM, Barsness G, Chaitman BR, Chung SC, Faxon D, Feit F, Frye R, Genuth S, Green J, Hlatky M, Kelsey S, Kennedy F, Krone R, Nesto R, Orchard T, O'Rourke R, Rihal C, Tardif JC. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the BARI 2D Trial. Am Heart J. 2008;156;528-536.
14. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/ AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation. 2007;116: 2634-2653. (Pubitemid 350182388)
15. Chaitman BR, Zhou SH, Tamesis B, Rosen A, Terry AB, Zumbehl KM, Stocke K, Takase B, Gussak I, Rautaharju PM. Methodology of serial ECG classification using an adaptation of the NOVACODE for Q wave myocardial infarction in the Bypass Angioplasty Revascularization Investigation (BARI). J Electrocardiol. 1996;29:265-277. (Pubitemid 26372513)
16. Rautaharju PM, Calhoun HP, Chaitman BR. NOVACODE serial ECG classification system for clinical trials and epidemiologic studies. J Electrocardiol. 1992;24(suppl):179-187.
17. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
18. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139
19. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
20. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KAA, Julian DG, Chamberlain DA, for the Second Randomized Intervention Treatment of Angina (RITA-2) Trial participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2003;42:1161-1170.
21. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009;373:911-918.
22. Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM. Insulin-sensitizing antihyper-glycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care. 2005; 28:1680-1689.
23. Sauer WH, Cappola AR, Berlin JA, Kimmel SE. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol. 2006;97:651-654.
24. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K. Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation: Intravascular ultrasound studies. J Diabetes Complicat. 2002;16:50-55.
25. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818-1820.
26. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452-3456.
27. Sobel BE, Taatjes DJ, Schneider DJ. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:1979-1989.
28. Kruszynska Y, Yu JG, Sobel BE, Olefsky JM. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes mellitus and in lean and obese normal subjects. Diabetes. 2000;49:633-639.
29. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation. 1999;99:2496-2498.
30. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8: 1245-1255.
31. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a mul-tifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
32. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
33. Passermani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery: survival of patients with a low ejection fraction. N Engl J Med. 1985;312:1665-1671.
34. Aldridge HE, Trimble AS. Progression of proximal coronary artery lesions to total occlusion after aorto-coronary bypass saphenous bypass grafting. J Thorac Cardiovasc Surg. 1971;62:7.
35. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol. 2009;54:558-565.
36. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A. Novel Approaches for Preventing or Limiting Events (Naples) II trial. J Am Coll Cardiol. 2009 Aug 3 [Epub ahead of print].
37. Gavard JA, Chaitman BR, Sakai S, Stocke K, Danchin N, Erhardt L, Gallo R, Chi E, Jessel A, Theroux P, for the GUARd During Ischemia Against Necrosis (GUARDIAN) Investigators. Prognostic significance of elevated CK-MB after coronary bypass surgery and after an acute coronary syndrome: results from the GUARDIAN trial. J Thorac Cardiovasc Surg. 2003;126: 807-813.
38. Klatte K, Chaitman BR, Theroux P, Gavard JA, Stocke K, Boyce S, Bartels C, Keller B, Jessel A, for the GUARDIAN Investigators. Increased mortality after coronary artery bypass grafting is associated with increased levels of postoperative CK-MB release: results from the GUARDIAN trial. J Am Coll Cardiol. 2001;38:1070-1077.
39. Mohammed AA, Agnihotri AK, van Kimmenade RRJ, Martinez-Rumayor A, Green SM, Quiroz R, Januzzi JL. Prospective, compre-hensive assessment of cardiac troponin T testing after coronary artery bypass graft surgery. Circulation. 2009;120:843-850.
40. Hueb W, Gersh BJ, Costa F, Lopes N, Soares PR, Dutra P, Jatene F, Pereira AC, Gois AFT, Oliveira SA, Ramires JAF. Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease. Ann Thorac Surg. 2007;83:93-99.
41. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Busse JB, Cohen DJ, Mahoney E, Sleeper L, King S, Domanski M, McKinlay S, Fuster V. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J. 2008;155:215-223.